EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation

Myung Geun Song, Keon Wook Kang iD

Cells · 29.06.2026 · 15 (13) · 1180

DOI: 10.3390/cells15131180 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 29.06.2026. Verfasst von Myung Geun Song und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea. Hauptthemen laut MEDLINE: Glioblastoma, Albumins, Drug Delivery Systems, Brain Neoplasms. Die Arbeit nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea, the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glioblastoma remains the most aggressive primary brain malignancy, with poor survival despite maximal safe resection, radiotherapy, and temozolomide-based chemotherapy. A major obstacle to effective treatment is the spatially heterogeneous blood–brain barrier/blood–tumor barrier, which restricts drug penetration into infiltrative tumor regions and limits uniform intratumoral exposure. Albumin-based delivery is attractive in glioblastoma because it addresses several formulation-level barriers at once: poor aqueous solubility of hydrophobic payloads, short systemic exposure, and the need for a biocompatible carrier that can interact with albumin-handling pathways such as gp60/albondin, SPARC, FcRn, and caveolin-associated transport. This review examines albumin-based strategies explored for glioblastoma, with an emphasis on albumin-bound paclitaxel nanoparticles, engineered albumin nanoparticles, dual-payload systems, albumin-binding photosensitizers, macrophage-assisted delivery, and albumin-bound pathway-directed agents. Preclinical evidence suggests that these platforms can improve brain-tumor drug exposure, support rational combinations, and synergize with BBB/BTB-opening technologies. Early clinical studies combining low-intensity pulsed ultrasound with microbubbles and albumin-bound paclitaxel provide human proof of concept for regional pharmacokinetic enhancement in recurrent glioblastoma, although survival benefit remains unproven. The available evidence supports albumin-based delivery as a rational formulation strategy. Its clinical value in GBM will depend on three testable requirements: spatial pharmacokinetic confirmation, biomarker-guided patient selection, and reproducible BBB/BTB modulation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaAlbuminsDrug Delivery SystemsBrain NeoplasmsHumansAnimalsBlood-Brain BarrierNanoparticlesTranslational Research, Biomedical

Stichwörter der Autor:innen

albumin nanoparticlesblood–brain barrierblood–tumor barrierfocused ultrasoundglioblastomanab-paclitaxeltranslational nanomedicine

Substanzen

Albumins

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.
  • Biomedical Research Institute, Seoul National University Hospital, Seoul 03080, Republic of Korea.
  • Department of Biomedical Sciences, Seoul National University Graduate School, Seoul 03080, Republic of Korea.
  • Cancer Research Institute, Seoul National University College of Medicine, Seoul 03080, Republic of Korea.

ORCID-Profile: Keon Wook Kang

Förderung

  • the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
  • the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea

Zitieren

APA

Song, M. G., & Kang, K. W. (2026). Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation. Cells, 15(13), 1180. https://doi.org/10.3390/cells15131180

Vancouver

Song MG, Kang KW. Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation. Cells. 2026;15(13):1180. doi:10.3390/cells15131180

BibTeX
@article{Song2026,
  author = {Song, Myung Geun and Kang, Keon Wook},
  title = {Albumin-Based Drug Delivery for Glioblastoma Treatment: Mechanistic Rationale, Preclinical Evidence, and Clinical Translation},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {1180},
  doi = {10.3390/cells15131180}
}
Kostenlos starten →